Cannabinoid compositions and dosage forms for intranasal or inhalational delivery
AssigneesRhodes Technologies, University of South Florida
InventorsChuanhai Cao, Ping Chang
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.
Claims5
A method of treating a neurological condition in a patient identified as in need thereof comprising the step of:
- administering to the patient, intranasally or through inhalation, formulated to target the brain of the patient a pharmaceutical composition comprising
- (i) a therapeutically effective amount of a cannabinoid selected from Δ9-THC and cannabinodiol (CBD), or a pharmaceutically acceptable salt or solvate thereof;
- and
- (ii) an amphiphilic copolymer comprising at least one hydrophilic component comprising polyethylene glycol (PEG) and at least one hydrophobic component selected from polycaprolactone (PCL), polylactic acid (PLA), poly lactide co-glycolide (PLGA), and a combination thereof;
- wherein the ratio of the cannabinoid to the amphiphilic copolymer is greater than 1:10 by weight, and said cannabinoid is encapsulated in said amphiphilic copolymer, and wherein said neurological condition is selected from Alzheimer's disease, Parkinson's disease, neuropathic pain, spasticity, spinal-cord-injury-induced pain, migraines, multiple sclerosis, Tourette Syndrome, and post-traumatic stress disease (PTSD).
Dependencies are inferred from the claim text.